Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Eurofins Ntd Llc |
RCV000179404 | SCV000231649 | uncertain significance | not provided | 2014-11-26 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000525446 | SCV000642371 | likely benign | Autosomal recessive distal spinal muscular atrophy 1; Charcot-Marie-Tooth disease axonal type 2S | 2025-01-20 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV000179404 | SCV001813638 | uncertain significance | not provided | 2024-06-29 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 24388491, 25439726, 22965130) |
| Ambry Genetics | RCV002426859 | SCV002677143 | uncertain significance | Inborn genetic diseases | 2023-01-03 | criteria provided, single submitter | clinical testing | The c.832C>G (p.H278D) alteration is located in exon 6 (coding exon 6) of the IGHMBP2 gene. This alteration results from a C to G substitution at nucleotide position 832, causing the histidine (H) at amino acid position 278 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Revvity Omics, |
RCV000179404 | SCV003813328 | uncertain significance | not provided | 2020-01-31 | criteria provided, single submitter | clinical testing | |
| Mayo Clinic Laboratories, |
RCV000179404 | SCV004226195 | uncertain significance | not provided | 2022-04-22 | criteria provided, single submitter | clinical testing |